US5844108AExpiredUtility
Primers targeted to NAT2 gene for detection of poor metabolizers of drugs
Est. expiryJun 22, 2010(expired)· nominal 20-yr term from priority
Inventors:Urs Meyer
C12Q 1/6883C12N 9/00C12N 9/0004C12N 9/1029C12N 15/10C12Q 1/6876C12Q 2600/156
56
PatentIndex Score
16
Cited by
60
References
7
Claims
Abstract
A method for the detection of poor metabolizers of drugs using PCR technology is described comprising a) optionally amplifying a gene coding for an enzyme known to be responsible for the metabolization of drugs, thereby separating it from possible closely related pseudogens, b) amplifying different allelic forms of the gene of step a) and c) detecting the product of step b). Primers for amplification of the genes responsible for the debrisoquine or acetylation phenotype are also disclosed.
Claims
exact text as granted — not AI-modifiedI claim:
1. A primer comprising a nucleic acid sequence of 10 to 25 bases, said primer being capable of amplifying a nucleic acid sequence of an allele of the NAT2 gene coding for the enzyme N-acetyltransferase, said sequence of said allele having a mutated or wild type sequence, said primer containing at the 3' end at least one base complementary to base number 282, 341, 481, 590, or 857 of the wild type or mutated NAT2 gene sequence and having bases in the 5' direction which are substantially complementary to said gene.
2. The primer of claim 1, which comprises the sequence: 5' CTG ATT TGG TCC AG 3' (SEQ ID NO:10).
3. The primer of claim 1, which comprises the sequence: 5' CTG ATT TGG TCC AA 3' (SEQ ID NO:11).
4. The primer of claim 1 which comprises the sequence: 5' AAT AGT AAG GGA TC 3' (SEQ ID NO:15).
5. The primer of claim 1, which comprises the sequence: 5' AAT AGT AAG GGA TT 3' (SEQ ID NO:16).
6. The primer of claim 1, which comprises the sequence: 5' TTT ACG CTT GAA CCT CG 3' (SEQ ID NO:13).
7. The primer of claim 1, which comprises the sequence: 5' TTT ACG CTT GAA CCT CA 3' (SEQ ID NO:14).Join the waitlist — get patent alerts
Track US5844108A — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.